The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

OMB APPROVAL OMB Number: Estimated average burden hours per response:

Notice of Exempt Offering of Securities

1. Issuer's Identity					
CIK (Filer ID Number)	Previous Names	None	Entity Type		
0001427925	Surx, Inc.		X Corporation		
Name of Issuer	,		Limited Partnership		
ACELRX PHARMACEUTICALS INC			<u> </u>		
Jurisdiction of Incorporation/Org	anization		Limited Liability Company		
DELAWARE	•		General Partnership		
Year of Incorporation/Organizati	ion		Business Trust		
X Over Five Years Ago			Other (Specify)		
Within Last Five Years (Spe	ecify Year)		_		
Yet to Be Formed	iony roury				
ret to be Formed					
2. Principal Place of Business	and Contact Information				
Name of Issuer					
ACELRX PHARMACEUTICALS	INC				
Street Address 1		Street Address 2			
351 GALVESTON DRIVE					
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer		
EDWOOD CITY CALIFORNIA 94063		94063	650-216-3500		
3. Related Persons					
Last Name	First Name		Middle Name		
King	Richard				
Street Address 1	Street Address 2				
c/o AcelRx Pharmaceuticals, Inc.	351 Galveston Driv	e			
City	State/Province/Co	untry	ZIP/PostalCode		
Redwood City CALIFORNIA			94063		
Relationship: X Executive Office	cer X Director Promoter				
Clarification of Response (if Nec	essary):				
Last Name	First Name		Middle Name		
Palmer	Pamela				
Street Address 1	Street Address 2				
c/o AcelRx Pharmaceuticals, Inc.	351 Galveston Driv	e			
City	State/Province/Co	untry	ZIP/PostalCode		
Redwood City	CALIFORNIA		94063		
Relationship: X Executive Office	cer X Director Promoter				
Clarification of Response (if Nec	essary):				
Last Name	First Name		Middle Name		
Welch	James				
Street Address 1	Street Address 2				
c/o AcelRx Pharmaceuticals, Inc.	351 Galveston Driv	e			

City	State/Province/Country	ZIP/PostalCode
Redwood City	CALIFORNIA	94063
Relationship: X Executive Officer	Director Promoter	
Clarification of Response (if Necessa	ary):	
Last Name	First Name	Middle Name
Hamel	Larry	
Street Address 1	Street Address 2	
c/o AcelRx Pharmaceuticals, Inc.	351 Galveston Drive	
City	State/Province/Country	ZIP/PostalCode
Redwood City	CALIFORNIA	94063
Relationship: X Executive Officer	Director Promoter	
Clarification of Response (if Necessa	ary):	
Last Name	First Name	Middle Name
Dasu	Anil	
Street Address 1	Street Address 2	
c/o AcelRx Pharmaceuticals, Inc.	351 Galveston Drive	
City	State/Province/Country	ZIP/PostalCode
Redwood City	CALIFORNIA	94063
Relationship: X Executive Officer		
	_	
Clarification of Response (if Necessa	ary):	
Last Name	First Name	Middle Name
Rosen	Howie	
Street Address 1	Street Address 2	
c/o AcelRx Pharmaceuticals, Inc.	351 Galveston Drive	
City	State/Province/Country	ZIP/PostalCode
Redwood City	CALIFORNIA	94063
Relationship: Executive Officer	_	
Clarification of Response (if Necessa	ary):	
Last Name	First Name	Middle Name
Nohra	Guy	
Street Address 1	Street Address 2	
c/o Alta Partners	One Embarcadero Center, 37th Floor	
City	State/Province/Country	ZIP/PostalCode
San Francisco	CALIFORNIA	94111
Relationship: Executive Officer		
Clarification of Response (if Necessa		
Sameation of Nesponse (II Necessa	ai y j.	
Last Name	First Name	Middle Name
Hoffman	Stephen	
Street Address 1	Street Address 2	
c/o Skyline Venture Partners	525 University Avenue, #520	
City	State/Province/Country	ZIP/PostalCode
Palo Alto	CALIFORNIA	94301
Relationship: Executive Officer	_	
— Clarification of Response (if Necessa	ary):	
Last Name	First Name	Middle Name
		WINCHE MAINE
Wan	Mark Street Address 2	
Street Address 1	SHEEL AUUIESS Z	

c/o Three Arch Partners	3200 Alpine Road		
City	State/Province/Country	ZIP/PostalCode	
Portola Valley	CALIFORNIA	94028	
Relationship: Executive Officer X Direct	ctor Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Schreck	Thomas		
Street Address 1	Street Address 2		
c/o AcelRx Pharmaceuticals, Inc.	351 Galveston Drive		
City	State/Province/Country	ZIP/PostalCode	
Redwood City	CALIFORNIA	94063	
Relationship: Executive Officer X Direct	ctor Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Edwards	Mark		
Street Address 1	Street Address 2		
c/o AcelRx Pharmaceuticals, Inc.	351 Galveston Drive		
City	State/Province/Country	ZIP/PostalCode	
Redwood City Relationship: Executive Officer X Direct	CALIFORNIA	94063	
Clarification of Response (if Necessary):			
4. Industry Group Agriculture	Health Care	Retailing	
Banking & Financial Services	Biotechnology	Restaurants	
Commercial Banking	Health Insurance	Technology	
Insurance	Usanitala 8 Dhysisiana		
Investing	Hospitals & Physicians	Computers	
Investment Banking	X Pharmaceuticals	Telecommunications	
Pooled Investment Fund	Other Health Care	Other Technology	
Is the issuer registered as	Manufacturing	 Travel	
an investment company under the Investment Company	Real Estate	Airlines & Airports	
Act of 1940?	Commercial		
Yes No	Construction	Lodging & Conventions	
Other Banking & Financial Services	REITS & Finance	Tourism & Travel Services	
Business Services	Residential	Other Travel	
Energy		Other	
Coal Mining	Other Real Estate	_	
Electric Utilities			
Energy Conservation			
Environmental Services			
Oil & Gas			
Пош			
Other Energy			

No Revenues	No Aggregate Net Asset Value
\$1 - \$1,000,000	\$1 - \$5,000,000
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,000,000
Over \$100,000,000	Over \$100,000,000
X Decline to Disclose	Decline to Disclose
Not Applicable	Not Applicable
6. Federal Exemption(s) and Exclusion(s) Claime	ed (select all that apply)
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505
Rule 504 (b)(1)(i)	X Rule 506
Rule 504 (b)(1)(ii)	Securities Act Section 4(6)
Rule 504 (b)(1)(iii)	Investment Company Act Section 3(c)
	Section 3(c)(1) Section 3(c)(9)
	Section 3(c)(2) Section 3(c)(10)
	Section 3(c)(3) Section 3(c)(11)
	Section 3(c)(4) Section 3(c)(12)
	Section 3(c)(5) Section 3(c)(13)
	Section 3(c)(6) Section 3(c)(14)
	Section 3(c)(7)
7. Type of Filing	
X New Notice Date of First Sale 2012-06-01	First Sale Yet to Occur
Amendment	not due l'ot to docui
8. Duration of Offering	
Does the leaver intend this offering to lest more the	in one year? Yes X No
Does the Issuer intend this offering to last more that	in one year? The X No
9. Type(s) of Securities Offered (select all that ap	ply)
X Equity	Pooled Investment Fund Interests
Debt	Tenant-in-Common Securities
X Option, Warrant or Other Right to Acquire Another	
Security to be Acquired Upon Exercise of Option	Warrant or Other
Right to Acquire Security	Other (describe)
10. Business Combination Transaction	
Is this offering being made in connection with a bus merger, acquisition or exchange offer?	iness combination transaction, such as a Yes X No
Clarification of Response (if Necessary):	
11. Minimum Investment	
Minimum investment accepted from any outside inv	vestor \$0 USD
12. Sales Compensation	

Recipient	Recipient CRD Number X None	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number $\overline{\mathbf{X}}$ None	
Street Address 1	Street Address 2	
City	State/Province/Country	ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States" or check individual States All States	Foreign/non-US	
13. Offering and Sales Amounts		
Total Offering Amount \$10,000,002 USD or Indefinite		
Total Amount Sold \$10,000,002 USD		
Total Remaining to be Sold \$0 USD or Indefinite		
Clarification of Response (if Necessary):		
Common Stock; Warrants to purchase Common Stock; Common Stock	issuable upon exercise of Warrants	
14. Investors		
Select if securities in the offering have been or may be sold to enter the number of such non-accredited investors who alread Regardless of whether securities in the offering have been or	ly have invested in the offering.	
investors, enter the total number of investors who already have		10
15. Sales Commissions & Finder's Fees Expenses		
Provide separately the amounts of sales commissions and finders estimate and check the box next to the amount.	fees expenses, if any. If the amount of an expenditure is no	t known, provide an
Sales Commissions \$0 USD Estimate		
Finders' Fees \$625,000 USD X Estimate		
Clarification of Response (if Necessary):		
16. Use of Proceeds		
Provide the amount of the gross proceeds of the offering that has be named as executive officers, directors or promoters in response box next to the amount.		
\$0 USD Estimate		
Clarification of Response (if Necessary):		
The proceeds will be used for general corporate purposes.		
Signature and Submission		
Please verify the information you have entered and review the file this notice.	Terms of Submission below before signing and clicking	SUBMIT below to
Terms of Submission		
In submitting this notice, each issuer named above is:		

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
ACELRX PHARMACEUTICALS INC	/s/ Mark B. Weeks	Mark B. Weeks	Secretary	2012-06-07

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.